Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
2023
DOI: 10.1016/j.molstruc.2022.134243
|View full text |Cite
|
Sign up to set email alerts
|

Discovery of oxazoline-triazole based hybrid molecules as DNA gyrase inhibitors: A new class of potential Anti-tubercular agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 44 publications
0
5
0
Order By: Relevance
“…48 The detailed procedure is given in our previously published paper. 49 In brief, various concentrations of test compounds were prepared in DMSO and added to the reaction mixture, followed by the addition of two units of the DNA gyrase enzyme. Ciprofloxacin was tested in the same experiment as the standard for comparison.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…48 The detailed procedure is given in our previously published paper. 49 In brief, various concentrations of test compounds were prepared in DMSO and added to the reaction mixture, followed by the addition of two units of the DNA gyrase enzyme. Ciprofloxacin was tested in the same experiment as the standard for comparison.…”
Section: Methodsmentioning
confidence: 99%
“…The assay was carried out using established protocols obtained from TopoGEN, Inc. (Buena Vista, Colorado, USA) . The detailed procedure is given in our previously published paper . In brief, various concentrations of test compounds were prepared in DMSO and added to the reaction mixture, followed by the addition of two units of the DNA gyrase enzyme.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Singh et al reported the antibacterial activity of aminopyrimidine-sulfonamide (APYS1) against M. tuberculosis. Figure 4 depicts the aminopyrimidine-sulfonamides (13)(14)(15) which exhibit low cytotoxicity and good potency against replicating M. tuberculosis (H37Rv). Among them, compound 13 showed the highest potency with a minimal bactericidal concentration (MBC99) of 0.6 mM, which is comparable to its minimal inhibitory concentration (MIC) of 0.3-0.6 mM.…”
Section: Sulfonamide Derivatives As Antimycobacterial Agentsmentioning
confidence: 99%
“…Sulphanilamide, the frst sulfonamide antibiotic, was initially synthesized in 1906 and later employed in the late 1930s as an antimicrobial agent [4]. For many years, sulfonamide has been utilized in a broad range of biological activities, including anti-HIV, antifungal, anticancer, antibacterial, antitumor, antituberculosis, antiinfammatory, insecticidal, antidiabetes, and antihepatitis applications [5][6][7][8][9][10][11][12][13]. Tese signifcant functions are attributed to biologically active molecules and their association with fve or six heterocyclicmembered rings linked to the sulfonyl group [14].…”
Section: Introductionmentioning
confidence: 99%